Skip to content
Screener

Gilead Sciences GILD Foreign Currency Translation Adjustment

Foreign Currency Translation Adjustment at other companies

Helmerich & Payne logo
Helmerich & PayneHP
$9.88M
Helmerich & Payne logo
Helmerich & PayneHP
$9.88M
Janus International Group logo
Janus International GroupJBI
-$100K-133%
Janus International Group logo
Janus International GroupJBI
$0
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
-$29K-867%
Flutter Entertainment logo
Flutter EntertainmentFLUT
$15.25M+655%

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$165.17B+10.5%
Enterprise value$188.24B+11.2%
P/S5.4×+0.2×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions)June 30, 2026 / Gross Carrying AmountJune 30, 2026 / Accumulated AmortizationJune 30, 2026 / Foreign Currency Translation AdjustmentJune 30, 2026 / Net Carrying AmountDecember 31, 2025 / Gross Carrying AmountDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Foreign Currency Translation AdjustmentDecember 31, 2025 / Net Carrying Amount
Intangible asset – sofosbuvir$10,720$(8,797)$1,923$10,720$(8,448)$2,272
Intangible asset – axicabtagene ciloleucel7,110(3,330)3,7807,110(3,127)3,983
Intangible asset – Trodelvy11,730(4,704)7,02611,730(4,164)7,566
Intangible asset – Hepcludex(1)1,395(462)933845(415)430
Other1,458(1,087)3721,483(1,056)428
Total finite-lived assets32,413(18,382)14,03231,888(17,211)14,678
Indefinite-lived assets – IPR&D(1)(2)2,3002,300
Total intangible assets$32,413$(18,382)$14,032$34,188$(17,211)$16,978

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's foreign currency translation adjustment?
Gilead Sciences (GILD) reported foreign currency translation adjustment of $0 in Q2 2026.
What does foreign currency translation adjustment mean?
Foreign Currency Translation Adjustment as reported by Gilead Sciences Inc.

Ask your AI about Gilead Sciences's foreign currency translation adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude